Confronto
Buserelin vs. DSIP
Due peptidi a confronto — identità, base di evidenze, stato legale ed eventi avversi noti.
Identità
Categoria
Ricerca (altro)
Ricerca (altro)
N. CAS
57982-77-1
62568-57-4
Peso molecolare
1239.42 g/mol
848.81 g/mol
Emivita
nessun dato
0.1 h
Sequenza
nessun dato
Trp-Ala-Gly-Gly-Asp-Ala-Ser-Gly-GluMeccanismo d'azione
Buserelin
Buserelin is a potent GnRH agonist: after an initial stimulatory surge ('flare'), continuous receptor occupancy causes downregulation and thereby suppression of LH, FSH and the downstream sex hormones.
DSIP
DSIP was described in 1977 by the Schoenenberger-Monnier group in Basel as a blood-borne substance reported to induce EEG changes similar to delta sleep in animal models. The exact mechanism remains undefined to this day: no defined receptor, proposed modulation of opioid, GABAergic and glutamatergic systems. Most mechanistic findings stem from preclinical studies of the 1980s and 1990s and were later subjected to contested replication attempts.
Base di evidenze
Evidenza più alta
RCT sull'uomo
Studio sull'uomo
Studi
0
4
di cui sull'uomo
0
1
Effetti registrati
2
3
Contraddizioni aperte
0
1
Eventi avversi documentati
1
1
Stato legale
Voci complete
Frequently asked questions
- What is the difference between Buserelin and DSIP?
- Buserelin is classified as "Ricerca (altro)", while DSIP is classified as "Ricerca (altro)". Buserelin: Buserelin is a synthetic GnRH agonist (including as a nasal spray). It is used in endometriosis, hormone-dependent prostate cancer and assisted reproduction; approved in Europe (Suprefact), not in the US. DSIP: Synthetic nonapeptide isolated in 1977 by Guido Monnier and Marcel Schoenenberger from the blood of rabbits in delta sleep. Despite the name, the role in sleep regulation is contested and not confirmed by Western RCTs in larger populations. This page contrasts both neutrally and source-based — with no usage or dosing recommendation.
- Which peptide is better supported by science, Buserelin or DSIP?
- The highest available evidence level is "RCT sull'uomo" for Buserelin and "Studio sull'uomo" for DSIP. A higher evidence level means more robust data, but says nothing about suitability for an individual. The full body of evidence is on each peptide's own page.
- What is the legal status of Buserelin and DSIP in Germany and the United States?
- Germania: Buserelin — Su prescrizione, DSIP — Non approvato. Stati Uniti: Buserelin — Non approvato, DSIP — Non approvato. These are factual summaries with source and review date on the individual pages.